0.70
Ovid Therapeutics Inc (OVID) 最新ニュース
What drives Ovid Therapeutics Inc. stock pricePhenomenal capital appreciation - Autocar Professional
Is Ovid Therapeutics Inc. a good long term investmentFree Wealth Planning Blueprint - Autocar Professional
12 Best Penny Stocks Under $1 to Buy Now - Insider Monkey
Ovid Therapeutics to Participate in the BTIG Virtual Biotech Conference - GlobeNewswire
What analysts say about Ovid Therapeutics Inc. stockBreakout profit opportunities - Autocar Professional
Ovid Therapeutics' Strategic Position in the Seizure and CNS Disorder Market: Pipeline Innovation and Partnership Potential - AInvest
Ovid Therapeutics to Participate in the BTIG Virtual Biotech Conference | OVID Stock News - GuruFocus
Brain Medicine Developer Ovid Therapeutics Reveals Latest Progress at Major BTIG Biotech Conference - Stock Titan
July 2025's Top Penny Stocks To Watch - simplywall.st
Ovid Therapeutics Stock Soars 13.88% on Investor Optimism - AInvest
Ovid Therapeutics Inc. Stock Analysis and ForecastFree Predictions - Autocar Professional
Ovid Therapeutics (NASDAQ:OVID) Receives Average Rating of “Buy” from Analysts - Defense World
Ovid Therapeutics (NASDAQ:OVID) Stock Rating Upgraded by Wall Street Zen - Defense World
What makes Ovid Therapeutics Inc. stock price move sharplyFree Access to Community with 300% Return - beatles.ru
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Ovid Therapeutics Surges 25% Amid Analyst Hype and Strategic Pipeline Progress - AInvest
Oliveda International, Inc. (OLVI) Announces Over 70% Growth in the First Half of 2025 - Yahoo.co
Why Ovid Therapeutics Inc. stock attracts strong analyst attentionDaily Breakout Picks - Newser
How Ovid Therapeutics Inc. stock performs during market volatilityTop Rated Trade Entries - Newser
Ovid Therapeutics (NASDAQ:OVID) Stock Price Down 2% – Time to Sell? - Defense World
Ovid Therapeutics Approves Key Proposals at Annual Meeting - The Globe and Mail
Local Bounti (LOCL) insider files Form 144 to sell 3,500 shares - Stock Titan
Ovid Therapeutics Sells Ganaxolone Royalties to Immedica - TipRanks
Balance Sheet Insights: Ovid Therapeutics Inc (OVID)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - DWinneX
Stoke Therapeutics: Impressive Pipeline And Big Backers - Seeking Alpha
Ovid Therapeutics Inc (OVID) Stock: The Story of a 52-Week Stock Range - investchronicle.com
Rising Leaders 2025: Ovid’s Meg Alexander On Neurology’s Next Frontier - insights.citeline.com
Safety scares and trial misses drag down neuro biotechs into Q2 - BioWorld MedTech
Transcript : Ovid Therapeutics Inc.Special Call - MarketScreener
Ovid Therapeutics Inc. (NASDAQ:OVID) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results - mx.advfn.com
Ovid Therapeutics (OVID) to Showcase Biomarker Advances in Epile - GuruFocus
Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025 | OVID Stock News - GuruFocus
Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025 - GlobeNewswire
大文字化:
|
ボリューム (24 時間):